CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that data from evaluations of a dual Toll-like Receptor 7 (TLR7) and TLR8 agonist and a TLR9 agonist in preclinical models of cancer will be presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO, April 18-22, 2009. The presentations are as follows:
